UK's Paravir develops anti-microbial for healthcare

This represents a world class solution to a global problem with low manufacturing cost. Paravir offers the opportunity to license or acquire novel technology for production of antimicrobial nonwoven fabrics. The Sage group is advising Paravir in their global search for manufacturing and distribution partners, the company said in  a press release.

Paravir has novel IP and core knowledge in the production of easily manufactured, low cost but highly effective, disposable, non-woven composite material with stringent anti-microbial properties. The manufacturing technology embodies a dry approach and can be incorporated on virtually all standard production lines for non-woven fabrics. Paravir’s innovative approach includes novel material composition and novel manufacturing technology. The active compound used is environmentally friendly, approved and generally regarded as safe. It is also low cost and is universally available.

The Paravir process uses impregnation of a dry non-metallic powder which is safe, readily available and low COGS. The resulting material is non-harmful to humans, animals, marine and plant life; it has been proven to eliminate >99.99% of all microbial activity in under 20 minutes, eliminating harmful bio-burden. Existing products in the market contain silver, copper and zinc.

The global presence of COVID-19 has highlighted the shortcomings of non- woven materials which generally lack anti-microbial properties. This is largely due to the cost and complexity associated with their manufacture. The present pandemic will persist for years, and other ever present epidemics re-enforce the need for effective, easily manufactured anti-microbial material, particularly in the surgical and healthcare arena, according to Paravir.

“Paravir’s highly innovative lead product has potential applications in any healthcare modality requiring a disposable material with anti-microbial properties, particularly face masks, curtains, wound dressings, gowns, bed linen, and apparel for patients and staff. Paravir looks forward to interacting with commercial and manufacturing partners worldwide,” Timothy Laing, CEO of Paravir, said in a statement.

Fibre2Fashion News Desk (GK)